Pyxis Oncology Reports Q1 Loss and Business Update

Pyxis Oncology ( (PYXS) ) has shared an announcement.

On May 15, 2025, Pyxis Oncology reported its first-quarter financial results and provided a business update, highlighting promising preclinical data for its lead candidate, micvotabart pelidotin (MICVO). The company is on track to report preliminary data from ongoing Phase 1 trials of MICVO, both as a monotherapy and in combination with pembrolizumab, later in 2025. Financially, Pyxis Oncology reported a net loss of $21.2 million for the quarter ended March 31, 2025, with increased research and development expenses attributed to clinical trial-related activities. The company maintains a cash runway expected to extend into the second half of 2026.

The most recent analyst rating on (PYXS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Pyxis Oncology stock, see the PYXS Stock Forecast page.

Spark’s Take on PYXS Stock

According to Spark, TipRanks’ AI Analyst, PYXS is a Neutral.

Pyxis Oncology’s score reflects ongoing financial challenges with significant cash burn and unprofitability. While there are positive developments with the strategic focus on its lead candidate, technical indicators suggest caution. Valuation remains unattractive due to negative earnings. The company’s future hinges on successful execution of its strategic initiatives.

To see Spark’s full report on PYXS stock, click here.

More about Pyxis Oncology

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation ADC therapeutics for difficult-to-treat cancers. The company is advancing its lead candidate, micvotabart pelidotin (MICVO), in clinical studies targeting recurrent and metastatic head and neck squamous cell carcinoma and other advanced solid tumors.

Average Trading Volume: 564,461

Technical Sentiment Signal: Sell

Current Market Cap: $73.72M

See more insights into PYXS stock on TipRanks’ Stock Analysis page.